Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In 2016, we have a bevy of oral anticoagulants that are approved for stroke prevention in patients with atrial fibrillation. Non–vitamin K oral anticoagulants (NOACs) are increasingly prescribed, and some guidelines recommend their use over vitamin K antagonists.1 As a consequence, clinicians and patients have more choices and need more data to best balance risks and benefits for each individual.
Parks AL, Redberg RF. Comparing Non–Vitamin K Oral AnticoagulantsWhere We Are Now. JAMA Intern Med. Published online October 03, 2016. doi:10.1001/jamainternmed.2016.6429